Shares of MorphoSys AG (ETR:MOR) have earned an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is €79.00 ($92.94).
A number of analysts recently issued reports on the stock. J P Morgan Chase & Co set a €62.00 ($72.94) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a research note on Friday, August 4th. Berenberg Bank set a €68.00 ($80.00) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price target on shares of MorphoSys AG and gave the stock a “neutral” rating in a research note on Monday, July 17th. Commerzbank Ag set a €76.00 ($89.41) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Wednesday, September 6th. Finally, Deutsche Bank AG set a €90.00 ($105.88) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Tuesday, August 1st.
MorphoSys AG (MOR) traded down 0.03% on Wednesday, hitting €74.78. 1,440 shares of the company were exchanged. The firm has a 50 day moving average of €71.83 and a 200-day moving average of €63.21. The stock’s market cap is €2.17 billion. MorphoSys AG has a 52-week low of €37.50 and a 52-week high of €80.67.
ILLEGAL ACTIVITY WARNING: “MorphoSys AG (MOR) Given Average Recommendation of “Buy” by Brokerages” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/10/30/morphosys-ag-mor-given-average-recommendation-of-buy-by-brokerages.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.